Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 3879505

Improved assay for total hemolytic complement.

R J Clark·A R Tschida·H Markowitz
View original source ↗Export metadata ↓

Abstract

Analysis of human serum for total hemolytic complement (CH50) is useful in following the course of patients who have diseases such as lupus nephritis or hypocomplementemic glomerulonephritis. A semi-automated system has been devised that facilitates test performance and reduces cost. An Autoprep dilutor is driven by an Apple IIe microprocessor. Samples are picked up, diluted with buffer, and added to a 96-well flat-bottom Linbro plate in a final volume of 100 microliters. Sensitized sheep RBC (100 microliters) are then added to each well. The plate is incubated at 37 degrees C for 90 min, agitated on a shaker, and then read by a Dynatech MR600 plate reader at 630 nm. The microprocessor converts the reading to percentage hemolysis by utilizing both a buffer blank and a complete hemolysis blank (saponin); these values are applied to the von Krogh equation to yield a CH50 value. Values obtained for normal human serum samples correlate well with those from an established semi-automated method (Technicon) in use in our laboratory.

Explore related subjects

Complement Fixation TestsComplement System ProteinsGlomerulonephritisHumansMicrocomputersNephritisComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R J Clark, A R Tschida, H Markowitz. 1985. Improved assay for total hemolytic complement.. https://pubmed.ncbi.nlm.nih.gov/3879505/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

The detection by enzyme-linked immunosorbent assays of non-complement-fixing HLA antibodies in transfusion medicine.

BACKGROUND: Noncomplement-fixing white cell antibodies have been demonstrated by the use of immunofluorescence flow cytometry against intact lymphocytes. However, such antibodies may be either HLA-specific or directed against other white cell antigens. Commercial enzyme-linked immunosorbent assay (ELISA) kits, using solubilized HLA molecules as targets, enable such HLA-specific antibodies to be detected in patients who are refractory to platelet transfusion, patients experiencing febrile transfusion reactions, and patients whose sera give nonspecific hemagglutination in indirect antiglobulin tests. STUDY DESIGN AND METHODS: Sera from all three groups of patients, previously screened for cytotoxic antibodies by using complement-dependent lymphocytotoxicity, were re-investigated with commercial ELISA kits for HLA antibody screening and identification using the manufacturers' recommended test methods. RESULTS: Non-complement fixing HLA antibodies were detected by ELISA in many sera that were lymphocytotoxicity test-negative; that is, 14 (17.5%) of 80 from refractory patients, 8 (23.5%) of 34 from those with febrile reactions, and 11 (22.4%) of 49 from those with nonspecific hemagglutination in the direct antiglobulin test. However, not all cytotoxic white cell antibodies were detectable by ELISA: only 19 (82.6%) of 23, 19 (67.8%) of 28, and 11 (73.6%) of 49, respectively in the three groups. Similarly, only 143 (79.4%) of 181 cytotoxic sera with clear-cut HLA-A or -B locus specificities were detectable by ELISA. CONCLUSION: ELISAs detect some but not all clinically significant HLA antibodies, irrespective of their ability to fix complement in vitro.

Complement Fixation Tests↗
PubMed1995

Internal quality assurance in a clinical virology laboratory. II. Internal quality control.

AIMS: In April 1991 additional quality control procedures were introduced into the virology section of the Clinical Microbiology and Public Health Laboratory, Cambridge. Internal quality control (IQC) samples were gradually included in the serological assays performed in the laboratory and supplemented kit controls and standard sera. METHODS: From April 1991 to December 1993, 2421 IQC procedures were carried out with reference sera. RESULTS: The IQC samples were evaluated according to the Westgard rules. Violations were recorded in 60 of 1808 (3.3%) controls and were highest in the IQC samples of complement fixation tests (25/312 (8%) of controls submitted for complement fixation tests). CONCLUSIONS: The inclusion of IQC samples in the serological assays performed in the laboratory has highlighted batch to batch variation in commercial assays. The setting of acceptable limits for the IQC samples has increased confidence in the validity of assay results.

Complement Fixation Tests↗